Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Irritable Bowel Syndrome

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 89 articles: HTML format

Single Articles

November 2025
1. CHUAH KH, Loo QY, Loh AJC, Leong JY, et al
   Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice. Authors' Reply.
   Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70469.
   PubMed    
   
   
   
2. HALMOS EP, Gibson PR
   Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice.
   Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70452.
   PubMed    
   
   
   
3. SHIN A, Xu H, Sarnoff R, Church A, et al
   Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome.
   Aliment Pharmacol Ther. 2025;62:944-947.
   PubMed     Abstract available
   
   
   October 2025
4. CHUAH KH, Loo QY, Loh AJC, Leong JY, et al
   Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome.
   Aliment Pharmacol Ther. 2025 Oct 16. doi: 10.1111/apt.70420.
   PubMed     Abstract available
   
   
   
5. DILMAGHANI S, BouSaba J, Lupianez-Merly C, Prokop L, et al
   Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea.
   Aliment Pharmacol Ther. 2025 Oct 15. doi: 10.1111/apt.70390.
   PubMed     Abstract available
   
   
   
6. BUTT MF, Goodoory VC, Ng CE, Black CJ, et al
   Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom.
   Aliment Pharmacol Ther. 2025 Oct 8. doi: 10.1111/apt.70400.
   PubMed     Abstract available
   
   
   July 2025
7. BAILLIE S, Saxena S, Jayasooriya N, Bottle A, et al
   Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.
   Aliment Pharmacol Ther. 2025 Jul 2. doi: 10.1111/apt.70247.
   PubMed     Abstract available
   
   
   April 2025
8. KHUNSRIRAKSAKUL C, Ziegler O, Liu D, Kulaylat AS, et al
   The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population-Based Study.
   Aliment Pharmacol Ther. 2025 Apr 11. doi: 10.1111/apt.70147.
   PubMed     Abstract available
   
   
   February 2025
9. CAMILLERI M, Ford AC
   Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut-Brain Interaction of Lower Gastrointestinal Tract.
   Aliment Pharmacol Ther. 2025 Feb 2. doi: 10.1111/apt.18527.
   PubMed     Abstract available
   
   
   January 2025
10. SHIN A
    Editorial: Alpha(2)-Delta Ligands in Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2025 Jan 30. doi: 10.1111/apt.18528.
    PubMed    
    
    
    
11. HOUGHTON LA, Gao S, Gilbert SA, Coffin B, et al
    Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2025 Jan 15. doi: 10.1111/apt.18487.
    PubMed     Abstract available
    
    
    November 2024
12. BUTT MF, Corsetti M
    Editorial: Rebuilding Rome-Revising Diagnostic Criteria for Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2024 Nov 14. doi: 10.1111/apt.18400.
    PubMed    
    
    
    October 2024
13. GOODOORY VC, Riggott C, Khasawneh M, Black CJ, et al
    Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care.
    Aliment Pharmacol Ther. 2024 Oct 28. doi: 10.1111/apt.18363.
    PubMed     Abstract available
    
    
    
14. O'CONNOR A, Gill S, Neary E, White S, et al
    Impact of HADS Anxiety and Depression Scores on the Efficacy of Dietary Interventions for Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2024 Oct 11. doi: 10.1111/apt.18337.
    PubMed     Abstract available
    
    
    
15. RIGGOTT C, Ford AC, Gracie DJ
    Review article: The role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications.
    Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18192.
    PubMed     Abstract available
    
    
    August 2024
16. SHIN A
    Editorial: Disordered eating and irritable bowel syndrome-Do maladaptive eating and weight control behaviours increase risk of a maladaptive gut?
    Aliment Pharmacol Ther. 2024 Aug 28. doi: 10.1111/apt.18232.
    PubMed    
    
    
    
17. YANG K, Kwon S, Burton-Murray H, Kuo B, et al
    Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS).
    Aliment Pharmacol Ther. 2024 Aug 5. doi: 10.1111/apt.18197.
    PubMed     Abstract available
    
    
    
18. LUPIANEZ-MERLY C, Jencks K, Dilmaghani S, Ferber M, et al
    Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS-BAD.
    Aliment Pharmacol Ther. 2024;60:544-545.
    PubMed    
    
    
    June 2024
19. WAIDYARATNE G, Daboul J, Liyanarachchi S, Chakraborty S, et al
    The evaluation and analysis of irritable bowel syndrome-related short videos on social media (TikTok).
    Aliment Pharmacol Ther. 2024 Jun 10. doi: 10.1111/apt.18096.
    PubMed     Abstract available
    
    
    
20. SPERBER AD, Freud T, Palsson OS, Bangdiwala SI, et al
    The aging gastrointestinal tract: Epidemiology and clinical significance of disorders of gut-brain interaction in the older general population.
    Aliment Pharmacol Ther. 2024 Jun 4. doi: 10.1111/apt.18103.
    PubMed     Abstract available
    
    
    April 2024
21. ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
    Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
    Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
    PubMed     Abstract available
    
    
    February 2024
22. STALLER K, Ludvigsson JF
    Letter: Irritable bowel syndrome and antibiotics-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:422.
    PubMed    
    
    
    
23. LONGSTRETH GF
    Letter: Irritable bowel syndrome and antibiotics.
    Aliment Pharmacol Ther. 2024;59:421.
    PubMed    
    
    
    
24. BLACK CJ, Gracie DJ
    Editorial: A Mediterranean diet for IBS-Is healthy and inclusive eating the way forward?
    Aliment Pharmacol Ther. 2024;59:571-572.
    PubMed    
    
    
    January 2024
25. SHIN A
    Editorial: Antibiotics as a risk factor for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2024;59:130-131.
    PubMed    
    
    
    
26. CHANG HC, Gau SY
    Letter: antibiotics prescription and new-onset irritable bowel syndrome.
    Aliment Pharmacol Ther. 2024;59:299.
    PubMed    
    
    
    December 2023
27. STALLER K, Ludvigsson JF
    Letter: Antibiotics prescription and new-onset irritable bowel syndrome-Authors' reply.
    Aliment Pharmacol Ther. 2023 Dec 8. doi: 10.1111/apt.17827.
    PubMed    
    
    
    November 2023
28. STAUDACHER HM, Mahoney S, Canale K, Opie RS, et al
    Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Nov 15. doi: 10.1111/apt.17791.
    PubMed     Abstract available
    
    
    
29. DEVENNEY J, Hasan SS, Morris J, Whorwell PJ, et al
    Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis.
    Aliment Pharmacol Ther. 2023 Nov 5. doi: 10.1111/apt.17790.
    PubMed     Abstract available
    
    
    
30. EL-SALHY M, Gilja OH, Hatlebakk JG
    Letter: A step forward towards a standard FMT protocol for IBS.
    Aliment Pharmacol Ther. 2023;58:1115-1116.
    PubMed    
    
    
    
31. LESMANA E, Grover M
    Editorial: Faecal microbiota transplantation in IBS-Moving closer or away from success?
    Aliment Pharmacol Ther. 2023;58:950-951.
    PubMed    
    
    
    
32. SU Q, Yau YK, Ng SC
    Editorial: Faecal microbiota transplantation in IBS-Moving closer or away from success? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:952-953.
    PubMed    
    
    
    October 2023
33. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    PubMed     Abstract available
    
    
    September 2023
34. STALLER K, Olen O, Soderling J, Roelstraete B, et al
    Antibiotic use as a risk factor for irritable bowel syndrome: Results from a nationwide, case-control study.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17736.
    PubMed     Abstract available
    
    
    
35. YAU YK, Su Q, Xu Z, Tang W, et al
    Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2023 Sep 5. doi: 10.1111/apt.17703.
    PubMed     Abstract available
    
    
    
36. MELTON SL, Halmos EP
    Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:554-555.
    PubMed    
    
    
    August 2023
37. CHUAH KH, Black CJ, Tee V, Lim SZ, et al
    Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply.
    Aliment Pharmacol Ther. 2023;58:476-477.
    PubMed    
    
    
    
38. GHOSHAL UC
    Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never!
    Aliment Pharmacol Ther. 2023;58:474-475.
    PubMed    
    
    
    July 2023
39. LUO Y, Jodorkovsky D, Singh P, Keefer LA, et al
    Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:137-138.
    PubMed    
    
    
    
40. DAI C, Huang YH, Jiang M
    Letter: Post-COVID-19 functional dyspepsia and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:126-127.
    PubMed    
    
    
    
41. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2023;58:139-140.
    PubMed    
    
    
    
42. MARASCO G, Maida M, Cremon C, Barbaro MR, et al
    Letter: Post-COVID-19 functional dyspepsia and irritable bowel syndrome-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:128-129.
    PubMed    
    
    
    June 2023
43. SO D, Yao CK, Gill PA, Thwaites PA, et al
    Detection of changes in regional colonic fermentation in response to supplementing a low FODMAP diet with dietary fibres by hydrogen concentrations, but not by luminal pH.
    Aliment Pharmacol Ther. 2023 Jun 30. doi: 10.1111/apt.17629.
    PubMed     Abstract available
    
    
    
44. WILSON B, Kanno T, Slater R, Rossi M, et al
    Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Jun 14. doi: 10.1111/apt.17609.
    PubMed     Abstract available
    
    
    
45. GUNN D, Ford A, Farrin A, Spiller R, et al
    Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1337-1338.
    PubMed    
    
    
    
46. SHAH ED
    Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms.
    Aliment Pharmacol Ther. 2023;57:1335-1336.
    PubMed    
    
    
    
47. CHUAH KH, Black CJ, Tee V, Lim SZ, et al
    A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care.
    Aliment Pharmacol Ther. 2023 Jun 1. doi: 10.1111/apt.17567.
    PubMed     Abstract available
    
    
    May 2023
48. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1190-1191.
    PubMed    
    
    
    
49. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1176-1177.
    PubMed    
    
    
    
50. SHARMA A, Rao S
    Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options!
    Aliment Pharmacol Ther. 2023;57:1174-1175.
    PubMed    
    
    
    
51. CHUAH KH, Mahadeva S
    Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients?
    Aliment Pharmacol Ther. 2023;57:1188-1189.
    PubMed    
    
    
    April 2023
52. MARASCO G, Maida M, Cremon C, Barbaro MR, et al
    Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17513.
    PubMed     Abstract available
    
    
    March 2023
53. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Mar 13. doi: 10.1111/apt.17465.
    PubMed     Abstract available
    
    
    
54. GUNN D, Topan R, Barnard L, Fried R, et al
    Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.
    Aliment Pharmacol Ther. 2023 Mar 3. doi: 10.1111/apt.17426.
    PubMed     Abstract available
    
    
    
55. THWAITES PA, Burgell RE
    Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here?
    Aliment Pharmacol Ther. 2023;57:723-724.
    PubMed    
    
    
    
56. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:725-726.
    PubMed    
    
    
    February 2023
57. MANTEGAZZA G, Gargari G, Guglielmetti S
    Editorial: bacterial gut symbionts as live biotherapeutic agents in irritable bowel syndrome-a rosy future despite potential long-term safety concerns.
    Aliment Pharmacol Ther. 2023;57:345-346.
    PubMed    
    
    
    
58. QUIGLEY EMM, Stevenson A, Jeffery I, Masters J, et al
    Editorial: bacterial gut symbionts as live biotherapeutic agents in IBS-a rosy future despite potential long-term safety concerns. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:347-348.
    PubMed    
    
    
    
59. WANG L, Alexander JA
    Letter: diet-responsive or just diet-adherent in EoE. Where is the dietitian? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:445.
    PubMed    
    
    
    January 2023
60. MAALOUF E, Grover M
    Editorial: repurposed linaclotide and the quest for abdominal pain management in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;57:261-262.
    PubMed    
    
    
    December 2022
61. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Dec 21. doi: 10.1111/apt.17356.
    PubMed     Abstract available
    
    
    
62. FITZPATRICK JA, Halmos EP
    Editorial: gluten-free but not pain-free in IBS.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    
    
    
    
63. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Editorial: gluten-free but not pain-free in IBS-authors' reply.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    
    
    
    November 2022
64. QUIGLEY EMM, Markinson L, Stevenson A, Treasure FP, et al
    Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Nov 11. doi: 10.1111/apt.17310.
    PubMed     Abstract available
    
    
    
65. LEMBO A, Kuo B, Boinpally R, Li E, et al
    Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2022 Nov 2. doi: 10.1111/apt.17274.
    PubMed     Abstract available
    
    
    
66. QUIGLEY EMM
    Editorial: 5-aminosalicylic acid fails to impact on irritable bowel syndrome-wrong population, intervention, target or hypothesis?
    Aliment Pharmacol Ther. 2022;56:1497-1498.
    PubMed    
    
    
    October 2022
67. GU Y, Xiang Y
    Letter: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:1215-1216.
    PubMed    
    
    
    
68. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Letter: efficacy of peppermint oil in irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1217-1218.
    PubMed    
    
    
    
69. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    PubMed    
    
    
    
70. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    PubMed    
    
    
    September 2022
71. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Sep 29. doi: 10.1111/apt.17239.
    PubMed     Abstract available
    
    
    
72. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:894-895.
    PubMed    
    
    
    
73. SHAH ED, Wechsler EV
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:892-893.
    PubMed    
    
    
    August 2022
74. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
    PubMed     Abstract available
    
    
    
75. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Aug 9. doi: 10.1111/apt.17179.
    PubMed     Abstract available
    
    
    
76. CASTRO TEJERA V, Ohman L, Aabakken L, Fellstrom B, et al
    Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-Effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
    Aliment Pharmacol Ther. 2022 Aug 8. doi: 10.1111/apt.17182.
    PubMed     Abstract available
    
    
    July 2022
77. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Impact of Rome IV Irritable Bowel Syndrome on Work and Activities of Daily Living.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17132.
    PubMed     Abstract available
    
    
    
78. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:160-161.
    PubMed    
    
    
    
79. MIKOCKA-WALUS A, Lores T
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:158-159.
    PubMed    
    
    
    
80. BIESIEKIERSKI JR, Wu J, Van Oudenhove L
    Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:368-369.
    PubMed    
    
    
    
81. HALMOS EP, Gibson PR
    Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs.
    Aliment Pharmacol Ther. 2022;56:366-367.
    PubMed    
    
    
    
82. BIESIEKIERSKI JR, Manning LP, Murray HB, Vlaeyen JWS, et al
    Review article: Exclude or expose? The paradox of conceptually opposite treatments for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Jul 1. doi: 10.1111/apt.17111.
    PubMed     Abstract available
    
    
    June 2022
83. COFFIN PB, Duboc H
    Diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Jun 2. doi: 10.1111/apt.17064.
    PubMed     Abstract available
    
    
    
84. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1590-1591.
    PubMed    
    
    
    
85. BERINSTEIN JA, Fendrick AM
    Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition.
    Aliment Pharmacol Ther. 2022;55:1588-1589.
    PubMed    
    
    
    May 2022
86. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
    Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16934.
    PubMed     Abstract available
    
    
    
87. QUIGLEY EMM
    Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?
    Aliment Pharmacol Ther. 2022;55:1218-1219.
    PubMed    
    
    
    
88. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
    Aliment Pharmacol Ther. 2022 May 1. doi: 10.1111/apt.16939.
    PubMed     Abstract available
    
    
    April 2022
89. FOX M
    Editorial: meal-induced symptoms in irritable bowel syndrome-"all in the mind"?
    Aliment Pharmacol Ther. 2022;55:880-881.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Irritable Bowel Syndrome is free of charge.